This simple daily activity may help you live longer and aid your heart
Climbing stairs instead of using the lift is associated with better heart health and a longer life, scientists say.
New research suggests regularly taking the stairs is linked to a 24% reduced risk of dying from any cause and a 39% lower likelihood of dying from heart disease.
The scientists said the findings, presented at the European Society of Cardiology's Preventive Cardiology conference in Athens, Greece, indicate that even short bursts of activity such as stair climbing could cut the risk of premature death.
Dr Sophie Paddock, of the University of East Anglia and Norfolk and Norwich University Hospital Foundation Trust, in Norwich, said: 'If you have the choice of taking the stairs or the lift, go for the stairs as it will help your heart.'
'Even brief bursts of physical activity have beneficial health impacts, and short bouts of stair climbing should be an achievable target to integrate into daily routines.'
Physical inactivity is associated with one in six deaths in the UK, according a report compiled by the Office for Health Improvement and Disparities.
Evidence suggests regular exercise can reduce the risk of early death and heart disease.
The NHS recommends at least 150 minutes of moderate-intensity exercise every week.
For the study, the team looked at data from nine studies involving more than 480,000 people, aged between 35 and 84 years.
Healthy individuals as well as patients with heart disease were included in the analysis, of whom 53% were women.
In addition to reducing the risk of premature death, stair climbing was also found to be associated with a lower risk of heart disease including heart attack, heart failure and stroke.
Dr Paddock said: 'Based on these results, we would encourage people to incorporate stair climbing into their day-to-day lives.
'Our study suggested that the more stairs climbed, the greater the benefits – but this needs to be confirmed.
'So, whether at work, home or elsewhere, take the stairs.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
15 hours ago
- Medscape
Two UK Cardiology Trials Struggle to Recruit Patients
MANCHESTER — Two ongoing cardiology trials in the UK are facing substantial recruitment challenges, researchers reported at the British Cardiovascular Society (BCS) Annual Conference 2025. The BRITISH study has enrolled fewer than one-third of its targeted 2504 patients over 2 years. Meanwhile, CRAAFT-HF has recruited just 22 of its 1200-patient goal since launching in December 2024. 'We are running behind schedule,' said Andrew Flett, a consultant cardiologist at University Hospital Southampton NHS Trust and principal investigator for BRITISH. 'We're running at about 50% of where we should be, and we're putting in every effort to try and improve that.' CRAAFT-HF's chief investigator Pier Lambiase, professor of cardiology at University College London, said that the trial's eligibility criteria were 'evolving' and being adjusted to boost recruitment. Entry Criteria Adjustments for CRAAFT-HF CRAAFT-HF is comparing surgical versus medical ablation of atrial fibrillation (AF) in people with heart failure and a reduced ejection fraction (EF) of 50%. The trial is still in its vanguard phase, with 14 centres open for an average of 4.5 months. The aim was to have at least 120-215 patients recruited across 10 sites within the first year. Professor Pier Lambiase Despite a large potential pool of patients with heart failure and AF seen in clinics, 'only about 5% are referred for ablation', Lambiase said. To improve recruitment, proposed changes include: Broadening the definition of AF to include paroxysmal and persistent types (up to 3 years' duration), confirmed by ECG, Holter monitoring, or cardiac implantable electronic devices (CIEDs). Relaxing inclusion thresholds for New York Heart Association (NYHA) class and LVEF thresholds. Removing NT-proBNP and medication optimisation criteria for trial eligibility. 'We've learned very quickly that this is threatening the trial,' Lambiase said. 'It's a lot of work to get the patient recruited, start optimal therapy, repeat the [echocardiogram], make sure they're still in the trial.' He estimated the revised criteria could have added 62 patients – tripling current enrolment. Lambiase remains optimistic, citing remote follow-up protocols and international collaboration plans with centres in Canada, Australia, Sweden, and Spain. Expanding the pool of associate principal investigators to include nurses and pharmacists may also help accelerate recruitment. The BRITISH Study The BRITISH study, active since 2023, is running at 46 of its planned 50 UK sites and actively recruiting. Ongoing since 2023, 46 out of the planned 50 sites are actively recruiting patients into the BRITISH study. It aims to determine whether scarring detected via cardiovascular magnetic resonance (CMR) is associated with reduced mortality in patients with nonischaemic cardiomyopathy and severe systolic heart failure (LVEF ≤35%) who receive implantable cardioverter defibrillators (ICDs). Andrew Flett Flett reported that of the 390 patients enrolled so far: Half were recruited within one year of diagnosis. Just under 20% were recruited within 6 months. Almost two-thirds had NYHA Class II heart failure. 38% had AF. Flett said this is 'the best-treated heart failure population in a heart failure trial that I'm aware of', noting high rates of evidence-based therapy: 93% on beta-blockers. 97% on antihypertensives. 92% on sodium-glucose cotransport 2 (SGLT2) inhibitors. 88% on mineralocorticoid receptor antagonists. The median age is 66 years. Most participants are White (93%) and male (80%). Addressing Gender Disparities in Trial Recruitment The under-representation of women — just 20% of the current cohort — is 'a major source of concern', Flett told Medscape News UK . The BCS and the British Heart Foundation Clinical Research Collaborative have previously highlighted the need to include more women in clinical trials. A consensus paper in the journal Heart , published at the start of the BCS annual conference, outlined strategies to improve female participation. However, Flett noted that nonischaemic cardiomyopathy is more common in men. 'We're going to recruit the patients that are there, and most of them are men,' he said. If we had 'the luxury of plenty of patients, we could obviously hold back on male recruitment', he added. Efforts are also underway to increase the number of female principal investigators (PIs). Currently, just 6 of the 46 site PIs are women. Recruitment could take another 2-3 years at the current pace. Plans are being considered to open additional sites in Australia and to remind UK centres of the importance of balanced gender recruitment. The BRITISH and CRAAFT-HF studies are funded by the British Heart Foundation. Flett and Lambiase had no conflicts of interest to disclose.
Medscape
a day ago
- Medscape
Study Supports Follow-Up Consultations After Heart Failure
About 40% of patients with diagnosed heart failure did not pursue future cardiology consultations, regardless of the initial severity of their condition. A single follow-up cardiology visit can reduce 1-year all-cause mortality by 6%-9%, with additional visits showing increased benefit as the severity of heart failure increases. METHODOLOGY: A nationwide cohort study included 655,919 French patients (median age, 80 years; 48% women) diagnosed or hospitalized with heart failure between January 1, 2015, and December 31, 2019, and who were still alive on January 1, 2020. Researchers categorized patients into four groups: Those hospitalized with heart failure within the past year, those hospitalized with the condition between 1 and 5 years prior, patients not hospitalized but who were receiving loop diuretics, and patients who were not hospitalized and were not taking loop diuretics. TAKEAWAY: The 1-year risk for all-cause mortality ranged from 8% in patients without hospitalization or use of loop diuretics to 25% for those hospitalized for heart failure within the past year. Mortality risk increased progressively across groups, with an adjusted hazard ratio of 1.61 for patients using loop diuretics, 1.83 for patients using loop diuretics and hospitalized over 1 year prior, and 2.32 for patients hospitalized less than 1 year prior ( P < .0001 for all). < .0001 for all). A single cardiology consultation was associated with a 6%-9% absolute reduction in 1-year all-cause mortality across all groups. The optimal follow-up strategy varied by risk group: One annual visit for low-risk patients, two to three visits for intermediate-risk patients, and four visits for high-risk patients recently hospitalized with heart failure. IN PRACTICE: 'Despite having an HF diagnosis, 40% of patients do not see a cardiologist annually, regardless of disease severity. Simple stratification based on hospitalization history and diuretic use effectively predicts outcomes. Tailoring the annual number of [heart failure] consultations according to this stratification could optimize resource use and reduce avoidable modelled deaths,' the researchers wrote. 'This group represents a significant opportunity to improve survival outcomes with only a modest increase in the total number of consultations. Healthcare systems could formally assess the impact of this annual consultation through large-scale cluster trials, allowing for an evaluation of the broader population-level benefits of this approach,' they added. SOURCE: The study was led by Guillaume Baudry, MD, of the Université de Lorraine in Nancy, France. It was published online in the European Heart Journal and presented at the Heart Failure Association of the European Society of Cardiology (HFA-ESC) 2025 meeting. LIMITATIONS: Researchers excluded patients residing in nursing homes due to their advanced prognosis and unavailability of healthcare utilization data, which may have led to an underestimation of morbidity and mortality. The study did not include heart failure patients who had not been recently hospitalized and did not submit long-term condition paperwork. Important clinical data such as ejection fraction, heart failure phenotype, and prognostic biomarker values were unavailable. DISCLOSURES: The researchers reported receiving fees and grants and other relationships with various pharmaceutical companies including Abbott, AstraZeneca, Bayer, and Pfizer.
Health Line
5 days ago
- Health Line
How Does Hypertrophic Cardiomyopathy Look Inside the Body?
Hypertrophic cardiomyopathy (HCM) is a condition that thickens some of the heart's muscles, making it harder to pump blood. Hypertrophic cardiomyopathy (HCM) usually affects the ventricular septum, which is located between your right and left ventricles (the lower chambers of your heart). A thicker ventricular septum takes up more space and can affect blood flow, especially through the left ventricle. HCM is genetic, so if one person has the condition, others in the family should also get checked. Symptoms include fatigue, dizziness, shortness of breath, chest pain, or an irregular heart rate. Sometimes, there are no symptoms. HCM can be diagnosed with an echocardiogram, a test that shows an image of your heart. Other tests may also be needed. Over time, HCM can worsen, so managing the condition is important. Many people with HCM take medications to manage their symptoms, while some need surgeries or procedures to improve blood flow through the heart. Explore what a typical heart looks like versus what it looks like with HCM in the interactive experience below.
